Adding yet another chapter to the Corporate Transparency Act (CTA) saga, the US Court of Appeals for the Fifth Circuit on December 26 issued an order vacating its stay of the Texas federal ...

FluoGuide A/S receives approval for phase II trial in head and neck cancerCopenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery ...

The Phase II Clinical Trial Application (CTA) for FG001 in head and neck cancer, announced on October 7, 2024, has been granted approval under the new European process by the Dutch Central ...